Literature DB >> 26284951

Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis.

Amara S Hussain1, Parameswaran Hari1, Ruta Brazauskas2, Carlos Arce-Lara1, Marcelo Pasquini1, Mehdi Hamadani1, Anita D'Souza1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26284951      PMCID： PMC4618044          DOI： 10.1002/ajh.24176

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

Authors:  S W Dubrey; D E Reece; V Sanchorawala; U Hegenbart; G Merlini; G Palladini; J-P Fermand; R A Vescio; J Bladé; L T Heffner; H Hassoun; X Liu; C Enny; P Ramaswami; Y Elsayed; H Van De Velde; S Mortimer; A Cakana; R L Comenzo
Journal:  QJM       Date:  2011-07-13

2.  Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.

Authors:  Angela Dispenzieri; David Dingli; Shaji K Kumar; S Vincent Rajkumar; Martha Q Lacy; Suzanne Hayman; Frances Buadi; Stephen Zeldenrust; Nelson Leung; Kristen Detweiler-Short; John A Lust; Stephen J Russell; Robert A Kyle; Morie A Gertz
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

3.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Authors:  Arnaud Jaccard; Raymond L Comenzo; Parameswaran Hari; Philip N Hawkins; Murielle Roussel; Pierre Morel; Margaret Macro; Jean-Luc Pellegrin; Estibaliz Lazaro; Dania Mohty; Patrick Mercie; Olivier Decaux; Julian Gillmore; David Lavergne; Frank Bridoux; Ashutosh D Wechalekar; Christopher P Venner
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

4.  Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.

Authors:  Efstathios Kastritis; Ashutosh D Wechalekar; Meletios A Dimopoulos; Giampaolo Merlini; Philip N Hawkins; Vittorio Perfetti; Julian D Gillmore; Giovanni Palladini
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

5.  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Authors:  Donna E Reece; Vaishali Sanchorawala; Ute Hegenbart; Giampaolo Merlini; Giovanni Palladini; Jean-Paul Fermand; Robert A Vescio; Xiangyang Liu; Yusri A Elsayed; Andrew Cakana; Raymond L Comenzo
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

6.  Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis.

Authors:  Satoshi Yamasaki; Tsuyoshi Muta; Taiki Higo; Hirotake Kusumoto; Eiko Zaitsu; Toshihiro Miyamoto; Yoshinao Oda; Koichi Akashi
Journal:  Hematol Rep       Date:  2013-09-16
  6 in total
  4 in total

Review 1.  Circulating Biomarkers for Cardiotoxicity Risk Prediction.

Authors:  Fei Fei Gong; Gregory J Cascino; Gillian Murtagh; Nausheen Akhter
Journal:  Curr Treat Options Oncol       Date:  2021-04-17

2.  Ubiquitin‑proteasomes are the dominant mediators of the regulatory effect of microRNA‑1 on cardiac remodeling after myocardial infarction.

Authors:  Liping Wei; Yufan Zhang; Xin Qi; Xuseng Sun; Yuanyang Li; Yue Xu
Journal:  Int J Mol Med       Date:  2019-09-04       Impact factor: 4.101

3.  Changes in patient-reported outcomes in light chain amyloidosis in the first year after diagnosis and relationship to NT-proBNP change.

Authors:  Anita D'Souza; Ruta Brazauskas; Angela Dispenzieri; Julie Panepinto; Kathryn E Flynn
Journal:  Blood Cancer J       Date:  2021-02-01       Impact factor: 11.037

Review 4.  Recent advances in understanding and treating immunoglobulin light chain amyloidosis.

Authors:  Talha Badar; Anita D'Souza; Parameswaran Hari
Journal:  F1000Res       Date:  2018-08-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.